Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435120 | 0.95 | AOC3 (0.45) | SCN3ASCN5ASCN9AAOC3TP53 | |
| SCHEMBL24434861 | 0.92 | AOC3 (0.48) | SCN3AAOC3ROCK2ROCK1TP53 | |
| SCHEMBL24434607 | 0.90 | KDM4E (0.47) | SCN3ASCN5ASCN9AAOC3ROCK2 | |
| SCHEMBL24434822 | 0.89 | MAPT (0.48) | AOC3ROCK2ROCK1CNR2MAOB | |
| SCHEMBL24434817 | 0.88 | SCD (0.47) | SCN3ASCN5ASCN9AAOC3TP53 | |
| SCHEMBL24435128 | 0.88 | ROCK2 (0.43) | SCN3ASCN5ASCN9AAOC3ROCK2 | |
| SCHEMBL24435091 | 0.87 | ROCK2 (0.46) | SCN3ASCN5ASCN9AAOC3ROCK2 | |
| SCHEMBL24435150 | 0.86 | PDE5A (0.47) | SCN3ASCN5ASCN9AAOC3ROCK2 | |
| SCHEMBL24434682 | 0.85 | SMN1; SMN2 (0.46) | SCN3ASCN5ASCN9ATP53CNR2 | |
| SCHEMBL24434744 | 0.83 | CSNK2A1 (0.47) | SCN3ASCN5ASCN9ATP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | SCN3A 1699/4885SCN5A 1768/4885SCN9A 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.